A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer.
Zhan G, Hu J, Da S, Weng J, Zhou C, Wen F, Liu S, Fang F, Shen E, Zhou Q, Luo P, Xu M, Zhan D, Su Y.
Zhan G, et al. Among authors: zhou q, zhou c.
Front Endocrinol (Lausanne). 2023 Jan 20;14:1110624. doi: 10.3389/fendo.2023.1110624. eCollection 2023.
Front Endocrinol (Lausanne). 2023.
PMID: 36742383
Free PMC article.